 |
인쇄하기
취소
|
Hanmi targets European market with Amosartan
Hanmi Pharm said on August 23 it is conducting a phase I clinical trial of Amosartan (amlodipine camsylate+losartan potassium), a hypertension combination drug in CCB + ARB class, to obtain an approval in EU.
Company officials said that if the clinical study is deemed successful, Amosartan will be available in European markets without delay.
Hanmi has performed the phase III trial of Amos...
Company officials said that if the clinical study is deemed successful, Amosartan will be available in European markets without delay.
Hanmi has performed the phase III trial of Amos...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.